Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan - 2Top 10 Arising Advances That Will Shape What's in store
- 3Palestinian leader Abbas says elections only after Gaza war ends
- 4The hunt for dark matter: a trivia quiz
- 5My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- Figure out how to Guarantee Your Dental Embeds Endure forever
- Examination In progress into Abuse of Japanese Government-Supported Advance
- Ukrainian foreign minister appeals for funds for drones
- EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- Excelling at Discussion: Genuine Examples of overcoming adversity
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
- Audits of 6 Specialty Mixed drinks
- Pick Your Favored pizza beating
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
